JDD Article Highlight
Rosacea’s hallmark redness stems from persistent changes in the skin’s blood vessels. But treatment options targeting these vessels are advancing. Alpha-agonists like oxymetazoline and brimonidine reduce redness, while beta-blockers and intradermal botulinum toxin (BTX) help control flushing.
Laser and light-based therapies complement these approaches by addressing deeper vascular changes. By targeting the skin’s vasculature and modulating the sympathetic nervous system, these therapies offer personalized solutions for managing rosacea’s visible symptoms.
In this JDD article, discover the latest vessel-targeting treatments in rosacea care.
